CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Monday, August 24, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TRIAL DATA
Phase Ib FIERCE Study Tests Trifluridine/Tipiracil With Radiation Before Rectal Cancer SurgeryA phase Ib trial evaluated the safety of combining trifluridine/tipiracil chemotherapy with radiation therapy before surgery in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)
-
LIVING WITH CRC
Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX ChemotherapyResearchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer)
-
RESEARCH
Genetic Changes Between Primary and Recurrent Rectal Cancer May Reveal New Treatment TargetsA study of 15 matched pairs of primary and locally recurrent rectal cancers found that recurrent tumors acquired new genetic alterations not present in the original tumor, including potentially actionable mutations in genes like KRAS, PIK3CA, MET, and FGFR. (Journal of Gastroenterology)
-
TRIAL DATA
Synthetic Control Arms From Historical Trial Data May Help Design Future Metastatic CRC TrialsResearchers used the ARCAD database to construct external control arms from historical trial data for seven landmark metastatic colorectal cancer trials, evaluating whether this approach could complement traditional randomized trials. (Journal of the National Cancer Institute)
Stay informed, stay hopeful—research continues to move forward.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data